Like many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.

To claim your copy free of charge simply follow this link.

Paul R. Kirchgraber net worth and biography

Paul Kirchgraber Biography and Net Worth

CEO of Laboratory Co. of America

Dr. Paul R. Kirchgraber serves as Executive Vice President and Chief Executive Officer - Covance Drug Development of the Company. From July 2018 until then, Dr. Kirchgraber served as Senior Vice President and head of Covance’s clinical trial testing solutions, and he served as Senior Vice President of Central Laboratories from April 2015 until July 2018. He served as Vice President and General Manager of Americas with Covance Central Laboratories from 2012 until 2015. Prior to that Dr. Kirchgraber served as Vice President Global Laboratory Operations and Medical Affairs with Covance Central Laboratory from 2009 – 2015. Prior to joining the Company, Dr. Kirchgraber also served at Quintiles Laboratories Ltd as Vice President and Global Medical Director where he was responsible for oversight of wholly owned laboratories in the U.S., Singapore, South Africa, India, and China and as Senior Director of Laboratory Services/ North American Medical Director where he had operational responsibility for laboratory and specimen management departments and was the medical director of the U.S. laboratory. Dr. Kirchgraber received his medical degree from Cornell University and his Master’s degree in Business Administration from Binghamton University, and he holds three board certifications from the American Board of Pathology.

What is Paul R. Kirchgraber's net worth?: The estimated net worth of Paul R. Kirchgraber is at least $3.08 million as of May 19th, 2023. Dr. Kirchgraber owns 12,946 shares of Laboratory Co. of America stock worth more than $3,079,206 as of November 21st. This net worth evaluation does not reflect any other assets that Dr. Kirchgraber may own. Learn More about Paul R. Kirchgraber's net worth.
How do I contact Paul R. Kirchgraber?: The corporate mailing address for Dr. Kirchgraber and other Laboratory Co. of America executives is 358 South Main Street, BURLINGTON NC, 27215. Laboratory Co. of America can also be reached via phone at (336) 229-1127 and via email at [email protected]. Learn More on Paul R. Kirchgraber's contact information.
Has Paul R. Kirchgraber been buying or selling shares of Laboratory Co. of America?: Paul R. Kirchgraber has not been actively trading shares of Laboratory Co. of America during the last ninety days. Most recently, Paul R. Kirchgraber sold 4,300 shares of the business's stock in a transaction on Friday, May 19th. The shares were sold at an average price of $216.91, for a transaction totalling $932,713.00. Following the completion of the sale, the chief executive officer now directly owns 12,946 shares of the company's stock, valued at $2,808,116.86. Learn More on Paul R. Kirchgraber's trading history.
Who are Laboratory Co. of America's active insiders?: Laboratory Co. of America's insider roster includes Kerrii Anderson (Director), Jean-Luc Belingard (Director), Lance Berberian (EVP), Brian Caveney (EVP), Jonathan DiVincenzo (EVP and President, Central Laboratories and International), Glenn Eisenberg (CFO), Dwight Gilliland (Director), Paul Kirchgraber (CEO), Peter Neupert (Director), Mark Schroeder (EVP), Amy Summy (CMO), Sandra van der Vaart (EVP), Peter Wilkinson (CAO), and R. Williams (Director). Learn More on Laboratory Co. of America's active insiders.
Are insiders buying or selling shares of Laboratory Co. of America?: During the last year, insiders at the medical research company sold shares 19 times. They sold a total of 96,112 shares worth more than $21,235,279.87. The most recent insider tranaction occured on November, 11th when CEO Adam H Schechter sold 6,189 shares worth more than $1,506,835.83. Insiders at Laboratory Co. of America own 0.9% of the company. Learn More about insider trades at Laboratory Co. of America.
Information on this page was last updated on 11/11/2024.

Paul R. Kirchgraber Insider Trading History at Laboratory Co. of America

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/19/2023	Sell	4,300	$216.91	$932,713.00	12,946
2/21/2023	Sell	8,000	$250.58	$2,004,640.00	9,069
5/6/2021	Sell	2,500	$276.55	$691,375.00	7,844
11/4/2020	Sell	1,500	$214.14	$321,210.00	7,698

Paul R. Kirchgraber Buying and Selling Activity at Laboratory Co. of America

Laboratory Co. of America Company Overview

Labcorp Holdings Inc. provides laboratory services. It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid, PAP, hemoglobin A1C and vitamin D, prostate-specific antigens, sexually transmitted diseases, hepatitis C, microbiology cultures and procedures, and alcohol and other substance-abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations (MCOs). In addition, the company offers online and mobile applications that enable patients to check test results; online applications for providers, MCOs, and accountable care organizations; specimen collection services; and drug development, medical device, and companion diagnostic development solutions, as well as support for crop protection and chemical testing. It serves pharmaceutical, biotechnology, medical device, and diagnostics companies; and MCOs, employer plans, other health insurance providers, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, crop protection and chemical companies, academic institutions, independent clinical laboratories, and retailers. The company was founded in 1995 is headquartered in Burlington, North Carolina.

Today's Range

Now: $237.85

$235.11

$238.68

50 Day Range

MA: $225.35

$212.04

$246.22

2 Week Range

Now: $237.85

$191.97

$247.99

Volume

476,603 shs

Average Volume

813,166 shs

Market Capitalization

$19.89 billion

P/E Ratio

46.01

Dividend Yield

1.21%

Beta

1.05

Download Our Tesla Ebook For Free

From DTI | Ad